📰 Zai Lab News
Page 34 - Zai Lab News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Zai Lab. Real-time updates on events, politics, business and more.
June 7, 2023
The company released a phase 3 trial regarding a non-small cell lung cancer therapy.
June 6, 2023
Enterprises accelerating AI Innovation in the MENA region
June 6, 2023
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with... | June 6, 2023
June 6, 2023
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for... | June 6, 2023
June 6, 2023
Shares of NovoCure Ltd. (NVCR) are slipping over 28% on Tuesday morning despite the company and Zai Lab (ZLAB) announcing that LUNAR study meets primary endpoint.
June 5, 2023
Vivo Capital LLC increased its holdings in Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 338,721 shares of the company’s stock after buying an additional 67,193 shares during the quarter. Zai […]
June 4, 2023
The CatGPT token a feline-esque ode to OpenAI's ChatGPT, has jumped by 3000% soon after landing on Uniswap.
June 3, 2023
Adding both durvalumab and olaparib to standard-of-care treatment in newly diagnosed non-BRCA mutated advanced ovarian cancer represents a huge step forward, says one expert.
June 3, 2023
CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab — followed by maintenance durvalumab, bevacizumab and olaparib — extended PFS compared with standard of care for women with non-BRCA-mutated advanced ovarian cancer.The findings of an interim analysis of the three-arm, randomized phase 3 DUO-O trial, presented at ASCO Annual Meeting, also noted a numerical
June 2, 2023
/PRNewswire/ -- The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.coms offering. The...